Vertex Pharmaceuticals (Mexico) Insiders
VRTX Stock | MXN 8,150 42.60 0.53% |
Vertex Pharmaceuticals employs about 4.8 K people. The company is managed by 29 executives with a total tenure of roughly 152 years, averaging almost 5.0 years of service per executive, having 165.52 employees per reported executive. Break down of Vertex Pharmaceuticals' management performance can provide insight into the company performance.
Amit Sachdev CEO Executive Vice President, Chief Regulatory Officer and Chief of Staff to the CEO |
Jeffrey Leiden Chairman Chairman of the Board, President, Chief Executive Officer |
Vertex |
Vertex Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of 0.1733 % which means that it generated a profit of $0.1733 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2767 %, meaning that it generated $0.2767 on every $100 dollars invested by stockholders. Vertex Pharmaceuticals' management efficiency ratios could be used to measure how well Vertex Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Vertex Pharmaceuticals Workforce Comparison
Vertex Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Biotechnology industry is at this time estimated at about 246,952. Vertex Pharmaceuticals claims roughly 4,800 in number of employees contributing just under 2% to stocks in Biotechnology industry.
The company has Profit Margin (PM) of 0.37 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.49 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.49. Vertex Pharmaceuticals Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Vertex Pharmaceuticals Price Series Summation is a cross summation of Vertex Pharmaceuticals price series and its benchmark/peer.
Vertex Pharmaceuticals Notable Stakeholders
A Vertex Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Vertex Pharmaceuticals often face trade-offs trying to please all of them. Vertex Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Vertex Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Amit Sachdev | Executive Vice President, Chief Regulatory Officer and Chief of Staff to the CEO | Profile | |
Jeffrey Leiden | Chairman of the Board, President, Chief Executive Officer | Profile | |
Reshma Kewalramani | Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer | Profile | |
Michael Parini | Executive Vice President, Chief Legal and Administrative Officer | Profile | |
John Gray | Senior Vice President Genetic Therapies | Profile | |
Paul Silva | Senior Vice President Corporate Controller | Profile | |
David Altshuler | Executive Vice President - Global Research, Chief Scientific Officer | Profile | |
Charles Wagner | Chief Financial Officer, Executive Vice President | Profile | |
Stuart Arbuckle | Executive Vice President Chief Commercial Officer | Profile | |
William Young | Independent Director | Profile | |
Alan Garber | Independent Director | Profile | |
Margaret McGlynn | Independent Director | Profile | |
Sangeeta Bhatia | Independent Director | Profile | |
Terrence Kearney | Independent Director | Profile | |
Bruce Sachs | Co-Lead Independent Director | Profile | |
Lloyd Carney | Independent Director | Profile | |
Yuchun Lee | Independent Director | Profile | |
Mike Tirozzi | SVP Officer | Profile | |
Damian Esq | Chief VP | Profile | |
Jeffrey MD | Ex Chairman | Profile | |
MD FASN | Pres CEO | Profile | |
Stuart BSc | Ex COO | Profile | |
Diana McKenzie | Independent Director | Profile | |
Nia Tatsis | Senior Vice President Chief Regulatory Officer | Profile | |
Kristen Ambrose | Tax, Accounting | Profile | |
Gerald Bruce | Executive Vice President Commercial Operations | Profile | |
Ourania Tatsis | Ex Officer | Profile | |
Susie Lisa | VP Relations | Profile | |
Carmen Bozic | Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer | Profile |
About Vertex Pharmaceuticals Management Performance
The success or failure of an entity such as Vertex Pharmaceuticals often depends on how effective the management is. Vertex Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Vertex management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Vertex management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. VERTEX PHARMACEUTICAL operates under Biotechnology classification in Mexico and is traded on Mexico Stock Exchange. It employs 3400 people.
Please note, the imprecision that can be found in Vertex Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Vertex Pharmaceuticals. Check Vertex Pharmaceuticals' Beneish M Score to see the likelihood of Vertex Pharmaceuticals' management manipulating its earnings.
Vertex Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Vertex Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Vertex Pharmaceuticals within its industry.Vertex Pharmaceuticals Manpower Efficiency
Return on Vertex Pharmaceuticals Manpower
Revenue Per Employee | 1.9M | |
Revenue Per Executive | 308M | |
Net Income Per Employee | 692.1K | |
Net Income Per Executive | 114.6M |
Additional Tools for Vertex Stock Analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.